Alpine Immune Sciences Stock (NASDAQ:ALPN)
Previous Close
$64.96
52W Range
$8.33 - $65.00
50D Avg
$52.49
200D Avg
$26.27
Market Cap
$4.46B
Avg Vol (3M)
$2.37M
Beta
0.97
Div Yield
-
ALPN Company Profile
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
ALPN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ANAB | AnaptysBio, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| TNYA | Tenaya Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| IGMS | IGM Biosciences, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| GLUE | Monte Rosa Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| BCYC | Bicycle Therapeutics plc |
| AMLX | Amylyx Pharmaceuticals, Inc. |